Elucidating the Mechanism of Ebola Virus Enterotoxigenicity
阐明埃博拉病毒肠毒性机制
基本信息
- 批准号:10025919
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Abdominal PainAfricaApicalBehaviorBiological AssayBiophysicsCalciumCase StudyCell Culture TechniquesCell membraneCellsCellular biologyCharacteristicsChloride ChannelsChloridesColonComplementConfocal MicroscopyDataDemocratic Republic of the CongoDevelopmentDiarrheaDoseEbola Hemorrhagic FeverEbola virusEbola virus envelope glycoproteinElectrical ResistanceElectrodesElectrolytesElectrophysiology (science)Endoplasmic ReticulumEnterotoxinsEnvironmental PollutionEpidemicEpithelialEpithelial CellsEpitheliumFamilyFecesFeverFilovirusFluids and SecretionsG-Protein-Coupled ReceptorsGastrointestinal tract structureGenomeGlucoseGlycoproteinsGoalsHeadacheHomeostasisHumanHypovolemic ShockImmunologyIntestinesIon ChannelIon TransportIonsKineticsLeadLiquid substanceLiteratureMeasuresMediatingMediator of activation proteinMembraneMembrane GlycoproteinsMicroscopyMolecularMolecular BiologyMonitorMovementMyalgiaNonstructural ProteinPathogenesisPathway interactionsPatientsPermeabilityPhenotypePhospholipase CPhysiologicalPlayProcessProteinsRNA VirusesRegulationResearchRiskRoleRotavirusSignal PathwaySmall IntestinesSodiumSourceStimulusSurfaceSymptomsSystemTechniquesTestingTrainingTranslatingVariantViralWaterabsorptionapical membranecareerdesigndiarrheal diseasedriving forceepithelial Na+ channelextracellulargastrointestinalgastrointestinal epitheliumhealth care settingshigh throughput screeningimprovedin vitro Assayintestinal epitheliummonolayermortalitynew therapeutic targetnoveloutcome forecastpatch clamppathogenpolarized cellresponsesecretion processskillstranslational impacttransmission processtreatment strategyviral transmissionvoltage
项目摘要
PROJECT SUMMARY
Ebola Virus Disease (EVD) is highly lethal with >20,000 cases reported during the 2014-16 West Africa epidemic
and >2,800 cases reported during the ongoing epidemic in the Democratic Republic of the Congo. Ebola virus
(EBOV) belongs to the Filoviridae family and encodes for 7 proteins including a single glycoprotein (EBOV-GP)
that has been shown to play a crucial role in EVD pathogenesis. During EVD, gastrointestinal fluid loss via large
volume watery diarrhea leads to hypovolemic shock, electrolyte imbalances, and increased mortality.
Furthermore, feces are categorized as highly infectious, thus excessive fluid loss incites environmental
contamination increasing the risk of nosocomial viral transmission. The physiological mechanisms of viral
glycoproteins acting as enterotoxins and prompting high volume diarrhea have been well described.
However, the molecular trigger and mechanisms describing how EBOV stimulates high volume watery diarrhea
during EVD have never been studied. Our preliminary data in human intestinal cells suggests an enterotoxin-
like behavior for EBOV-GP as it induces a rapid and dose-dependent increase in intracellular Ca2+
concentration that is mitigated by inhibition of Phospholipase C (PLC). Moreover, EBOV-GP stimulation
induces activation of chloride channels. The working hypothesis is that EBOV-GP induces intracellular Ca2+
increase in the gastroinstestinal epithelia, triggering an apical surface ion transport dysregulation resulting in
increased permeability and water secretion. The project goals are to determine if EBOV-GP acts as an
enterotoxin, study if it triggers a malabsorptive or secretory process and fully elucidate the mechanisms leading
to high-volume watery diarrhea during EVD. For this, the project has three specific aims conceptualized for using
of small intestine and colon cells since they diverge in absorption and secretion processes. Aim 1 will study the
contributions of Ca2+ sources in the increased levels of intracellular Ca2+ triggered by EBOV-GP and elucidate
its upstream signaling pathway. Aim 2 will assess the dynamics of Na+ and Cl- across the cell membrane, cell
permeability and fluid transport after EBOV-GP stimulation. Polarized cell cultures will be used to mimic the
ions/fluid movement and directionality. Aim 3 will feature whole-cell patch clamp to identify the ion channels
being altered by EBOV-GP. This project will be achieved using contemporary in-vitro assays and combine
microscopy, molecular biology, electrophysiology and biophysics. The completion of this project will provide the
awardee training in electrophysiology techniques advancing his career and complementing his immunology and
cell biology background. The proposed project will provide the awardee the skill set to study host-pathogen
interactions in the context of the interplay between electrophysiology, immunology and cell biology. This project
has translational impact as it could lead to novel therapeutic targets and strategies for EVD high volume diarrhea,
directly improving the patients prognosis and reducing viral transmission in healthcare settings in the field.
项目概要
埃博拉病毒病 (EVD) 具有高度致命性,2014-16 年西非疫情期间报告病例数超过 20,000 例
刚果民主共和国疫情期间报告了超过 2,800 例病例。埃博拉病毒
(EBOV) 属于丝状病毒科,编码 7 种蛋白质,包括单个糖蛋白 (EBOV-GP)
已被证明在埃博拉病毒病发病机制中发挥着至关重要的作用。在埃博拉病毒病期间,胃肠道液体通过大量流失
大量水样腹泻会导致低血容量性休克、电解质失衡和死亡率增加。
此外,粪便被归类为高度传染性的,因此过多的液体流失会导致环境污染。
污染增加了医院内病毒传播的风险。病毒的生理机制
糖蛋白作为肠毒素并引发大量腹泻已被充分描述。
然而,描述埃博拉病毒如何刺激大量水样腹泻的分子触发和机制
从未研究过 EVD 期间的情况。我们在人类肠道细胞中的初步数据表明,肠毒素
与 EBOV-GP 的行为类似,因为它会诱导细胞内 Ca2+ 快速且剂量依赖性增加
通过抑制磷脂酶 C (PLC) 可以降低浓度。此外,EBOV-GP刺激
诱导氯离子通道的激活。工作假设是 EBOV-GP 诱导细胞内 Ca2+
胃肠道上皮细胞增加,引发顶端表面离子转运失调,导致
增加渗透性和水分分泌。该项目的目标是确定 EBOV-GP 是否充当
肠毒素,研究它是否会引发吸收不良或分泌过程,并充分阐明导致的机制
EVD 期间出现大量水样腹泻。为此,该项目具有三个具体目标,旨在使用
小肠和结肠细胞的吸收和分泌过程不同。目标 1 将研究
Ca2+ 来源在 EBOV-GP 引发的细胞内 Ca2+ 水平增加中的贡献并阐明
其上游信号通路。目标 2 将评估 Na+ 和 Cl- 穿过细胞膜、细胞的动态
EBOV-GP 刺激后的渗透性和液体输送。极化细胞培养物将用于模拟
离子/流体运动和方向性。 Aim 3 将采用全细胞膜片钳来识别离子通道
被 EBOV-GP 改变。该项目将使用现代体外测定法并结合
显微镜、分子生物学、电生理学和生物物理学。该项目的完成将提供
获奖者接受电生理学技术培训,促进他的职业生涯并补充他的免疫学和
细胞生物学背景。拟议的项目将为获奖者提供研究宿主病原体的技能
电生理学、免疫学和细胞生物学之间相互作用的相互作用。本项目
具有转化影响,因为它可以为埃博拉病毒病大量腹泻带来新的治疗靶点和策略,
直接改善患者预后并减少现场医疗机构中的病毒传播。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19.
- DOI:10.1101/2021.02.21.432184
- 发表时间:2021-02-22
- 期刊:
- 影响因子:0
- 作者:Ko, Sung Hee;Mokhtari, Elham Bayat;Boritz, Eli A
- 通讯作者:Boritz, Eli A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marcos Javier Ramos-Benitez其他文献
Marcos Javier Ramos-Benitez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
非洲猪瘟病毒关键抗原表位筛选和功能验证
- 批准号:32302858
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非洲猪瘟病毒pS273R通过切割G3BP1调控宿主应激颗粒形成的机制
- 批准号:32302893
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
非洲猪瘟病毒B475L蛋白靶向LMP2抑制抗原递呈的分子机制
- 批准号:32302894
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于非洲猪瘟病毒pS273R蛋白泛素-蛋白酶体降解途径阻抑机制理性设计其特异性蛋白水解靶向嵌合体的研究
- 批准号:32373044
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
自噬在呋虫胺致非洲爪蟾脂质代谢紊乱中的调控机制研究
- 批准号:42307363
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE)
美国-尼日利亚癌症控制实施科学与公平研究中心 (C3-RISE)
- 批准号:
10738439 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity)
一旦被咬:获得疟疾适应性免疫(奥巴马 - 免疫)
- 批准号:
10753364 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Conserved mechanisms of ciliary signaling and cell-cell fusion
纤毛信号传导和细胞间融合的保守机制
- 批准号:
10522540 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Conserved mechanisms of ciliary signaling and cell-cell fusion
纤毛信号传导和细胞间融合的保守机制
- 批准号:
10707152 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
使用人单克隆抗体确定间日疟疾的保护性免疫目标
- 批准号:
10353401 - 财政年份:2020
- 资助金额:
-- - 项目类别: